UK scientist wins NC3Rs prize
For improving the welfare of laboratory mice
Prizewinner Jane Hurst's research has shown that a new way of handling laboratory mice can improve their welfare and the quality of the science they are used for.
Laboratory mice are usually picked up by their tails, which according to Hurst's study causes high levels of anxiety and stress to the animals that can influence the outcome of experiments. By simply catching the mice using a plastic tunnel or cupped hands anxiety can be greatly reduced.
The number of mice used in the UK annually is approximately 2.6 million.
Hurst, from the University of Liverpool, received a £10,000 prize grant, which is sponsored by GlaxoSmithKline (GSK), plus a personal award of £1,000. She plans to use the prize to provide training for scientists and animal care staff on handling methods and also to assess the effects of different handling methods on stress physiology.
‘I hope our research will be universally implemented across laboratories to improve animal welfare for all mice and to minimise the effects of handling on experiments. This is a small change that is easily applied and will make a big difference to animal welfare,’ she said.
The NC3Rs prize recognises and rewards excellence in research that helps to reduce the number and suffering of animals used for scientific purposes.
The Wellcome Trust and NC3Rs also funded the research.
The research was published in Nature Methods magazine.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Finance
Britain's biotech potential (part II): world-class science, second-class support?
In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Manufacturing
BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech
The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Finance
Sun Pharma to acquire Organon in $11.75bn deal, expanding global manufacturing and biosimilars reach
The firm will acquire Organon in an all-cash $11.75bn transaction, creating a larger global pharma group with expanded manufacturing capacity, stronger women's health operations and a top-10 biosimilars position
Manufacturing
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform
The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
Finance
UK biotech venture capital rises 17% in Q1 2026 as deal activity surges 67% year-on-year, BIA figures show
Total UK biotech equity financing reached £552m in the first quarter of 2026, driven by a 17% quarterly rise in venture capital investment, according to BioIndustry Association data, though public markets remain dormant with no IPOs recorded since 2022